Xalatan Related Published Studies
Well-designed clinical trials related to Xalatan (Latanoprost)
Twenty-four-hour intraocular pressure control with latanoprost-timolol-fixed combination versus bimatoprost in patients who switched from timolol. [2011.10]
A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. [2011.09]
Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension. [2011.08.19]
The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness. [2011.08]
Effect of latanoprost on choroidal blood flow regulation in healthy subjects. [2011.06.22]
The influence of topical diclofenac sodium on the ocular hypotensive effect of latanoprost in glaucoma patients. [2011.04]
Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension. [2011.04]
24-Hour intraocular pressure control between travoprost/timolol fixed combination, latanoprost/ timolol fixed combination and standard timolol in primary open angle glaucoma and ocular hypertension. [2011.03]
The impact of intraocular pressure reduction on retinal ganglion cell function measured using pattern electroretinogram in eyes receiving latanoprost 0.005% versus placebo. [2011.01.28]
Twenty-four-hour intraocular pressure control with latanoprost-timolol-fixed
combination versus bimatoprost in patients who switched from timolol. [2011]
Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost. [2010.11.03]
Comparison of Travoprost and Bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination. [2010.10]
24-h Intraocular pressure control with evening-dosed travoprost/timolol, compared with latanoprost/timolol, fixed combinations in exfoliative glaucoma. [2010.10]
Effects of topical administration of latanoprost, timolol, or a combination of latanoprost and timolol on intraocular pressure, pupil size, and heart rate in clinically normal dogs. [2010.09]
Efficacy and mechanisms of intraocular pressure reduction with latanoprost and timolol in participants with ocular hypertension: a comparison of 1 and 6 weeks of treatment. [2010.08]
Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension. [2010.07]
Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects. [2010.07]
A 12-week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapy. [2010.07]
Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial. [2010.06]
Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. [2010.02]
A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost. [2010.02]
Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. [2010.02]
A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension. [2010.02]
Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study. [2010.01]
Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/timolol versus latanoprost or timolol monotherapy. [2010.01]
Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in
open-angle glaucoma and ocular hypertension: 24-month results of a randomized,
double-masked phase III study. [2010]
A phase II study on the duration and stability of the intraocular
pressure-lowering effect and tolerability of Tafluprost compared with
latanoprost. [2010]
Fixed combination of latanoprost and timolol vs individual components for primary
open-angle glaucoma or ocular hypertension: a randomized, double-masked study. [2010]
A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial. [2009.10]
Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study. [2009.10]
Additive Intraocular Pressure Reduction Effect of Fixed Combination of Maleate Timolol 0.5%/Dorzolamide 2% (Cosopt) on Monotherapy With Latanoprost (Xalatan) in Patients With Elevated Intraocular Pressure: A Prospective, 4-week, Open-label, Randomized, Controlled Clinical Trial. [2009.09.02]
Pneumatic trabeculoplasty vs latanoprost as adjunctive therapy to timolol in primary open-angle glaucoma or ocular hypertension. [2009.08]
A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma. [2009.06]
Efficacy and safety of latanoprost in eyes with uveitic glaucoma. [2009.06]
24-hour intraocular pressure and blood pressure levels with latanoprost/timolol fixed combination versus timolol. [2009.05]
Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients. [2009.04]
Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. [2009.03]
The effect of latanoprost on ocular blood flow. [2009.02]
Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: A multicenter, randomized, investigator-masked, clinical study. [2009.01]
Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension. [2008.12]
Conjunctival hyperemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomized clinical trials. [2008.11.19]
Effects of the timolol-dorzolamide fixed combination and latanoprost on circadian diastolic ocular perfusion pressure in glaucoma. [2008.10]
Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma. [2008.09]
[Influence of topical latanoprost on foveal thickness in eyes that underwent uneventful cataract surgery] [2008.09]
The additive effects on intraocular pressure of combining nipradilol 0.25% and latanoprost 0.005% ophthalmic solutions: a prospective, randomized, multicenter study. [2008.09]
Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: a patient-use study. [2008.06.11]
Efficacy of latanoprost when stored at room temperature. [2008.06]
Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. [2008.05]
Topical and oral ketorolac administration increases the intraocular pressure-lowering effect of latanoprost. [2008.05]
Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. [2008.05]
Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost. [2008.04]
Circadian changes of intraocular pressure and ocular perfusion pressure after timolol or latanoprost in Caucasians with normal-tension glaucoma. [2008.03]
Comparison of twice-daily and three-times-daily dosing of dorzolamide in ocular hypertension and primary open-angle glaucoma patients treated with latanoprost. [2008.03]
Increase and decrease of measurements of iris density of glaucoma patients treated with latanoprost over 36 months. [2008.02]
Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment. [2008.01]
Intraocular pressure control with latanoprost/timolol and travoprost/timolol fixed combinations : a retrospective, multicentre, cross-sectional study. [2008]
Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure. [2007.12]
A 6-Week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%. [2007.09]
Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre study. [2007.06]
A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. [2007.05]
Retrobulbar haemodynamic effects of the latanoprost/timolol and the dorzolamide/timolol fixed combinations in newly diagnosed glaucoma patients. [2007.05]
Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on Circadian Intraocular Pressure. [2007.04.23]
Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. [2007.04]
Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. [2007.03]
Latanoprost versus timolol gel-forming solution once daily in primary open-angle glaucoma or ocular hypertension. [2007.02]
Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost. [2007]
24-Hour control with a latanoprost-timolol fixed combination vs timolol alone. [2006.11]
Travoprost versus latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progression. [2006.09]
Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. [2006.09]
Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial. [2006.08]
An evaluation of the rate of nonresponders to latanoprost therapy. [2006.06]
A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma. [2006.05]
A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. [2006.03]
Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication. [2006.03]
The effect of latanoprost, bimatoprost, and travoprost on intraocular pressure after cataract surgery. [2006.02]
Nimesulide oral administration increases the intraocular pressure-lowering effect of latanoprost in patients with primary open-angle glaucoma. [2006.02]
Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. [2006.02]
A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. [2006.01]
Prospective comparative switch study from timolol 0.5% and latanoprost 0.005% to bimatoprost 0.03%. [2006.01]
A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. [2006.01]
Comparison of the additive effects of nipradilol and carteolol to latanoprost in open-angle glaucoma. [2006.01]
Effects of latanoprost and betaxolol on cardiovascular and respiratory status of newly diagnosed glaucoma patients. [2006]
Comparison of latanoprost monotherapy and combined therapy of 0.5% timolol and 1% dorzolamide in chronic primary angle-closure glaucoma (CACG) in Japanese patients. [2005.12]
A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. [2005.11]
The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients. [2005.11]
The efficacy and ocular discomfort of substituting brinzolamide for dorzolamide in combination therapy with latanoprost, timolol, and dorzolamide. [2005.10]
Effects of intratympanic injection of latanoprost in Meniere's disease: a randomized, placebo-controlled, double-blind, pilot study. [2005.09]
Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. [2005.07]
Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies. [2005.06]
Effects of the combination of bimatoprost and latanoprost on intraocular pressure in primary open angle glaucoma: a randomised clinical trial. [2005.05]
Effects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: a randomized trial comparing bimatoprost and latanoprost with dorzolamide [ISRCTN18873428]. [2005.04.05]
The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta-blocker in patients with glaucoma. [2005.04]
24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. [2005.04]
Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States. [2005.04]
Degree of angle closure and the intraocular pressure-lowering effect of latanoprost in subjects with chronic angle-closure glaucoma. [2005.02]
Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. [2005.02]
Comparison of additional intraocular pressure-lowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol-dorzolamide combination. [2005.02]
A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients. [2004.12]
Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%. [2004.12]
[Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost] [2004.11]
Intraocular pressure fluctuations in response to the water-drinking provocative test in patients using latanoprost versus unoprostone. [2004.10]
|